Bioventus (BVS) Total Liabilities (2020 - 2026)

Bioventus (BVS) has 7 years of Total Liabilities data on file, last reported at $416.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 17.72% year-over-year to $416.3 million; the trailing twelve-month figure through Mar 2026 stood at $416.3 million (down 17.72% YoY), and the FY2025 full-year result was $455.1 million, down 16.09% from the prior year.
• Total Liabilities for Q1 2026 stood at $416.3 million, down from $455.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.0 billion in Q4 2022 and bottomed at $416.3 million in Q1 2026.
• The 5-year median for Total Liabilities is $584.6 million (2023), against an average of $614.7 million.
• The widest annual swing landed in 2022, when Total Liabilities soared 140.14%; it then tumbled 42.62% in 2023.
• A 5-year view of Total Liabilities shows it stood at $960.4 million in 2022, then sank by 38.59% to $589.8 million in 2023, then decreased by 8.04% to $542.4 million in 2024, then declined by 16.09% to $455.1 million in 2025, then decreased by 8.53% to $416.3 million in 2026.
• The last three Total Liabilities figures came in at $416.3 million (Q1 2026), $455.1 million (Q4 2025), and $494.3 million (Q3 2025), per Business Quant data.

Peer Comparison